Induced Pluripotent Stem Cells Production Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Process (Manual iPSC Production Process, Automated iPSC Production Process), By Product (Instruments/ Devices, Automated Platforms, Consumables & Kits, Services), By Application (Drug Development and Discovery, Regenerative Medicine, Toxicology Studies, Others),
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationInduced Pluripotent Stem Cells Production Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Process (Manual iPSC Production Process, Automated iPSC Production Process), By Product (Instruments/ Devices, Automated Platforms, Consumables & Kits, Services), By Application (Drug Development and Discovery, Regenerative Medicine, Toxicology Studies, Others),
| Forecast Period | 2024-2028 |
| Market Size (2022) | USD 1.24 billion |
| CAGR (2023-2028) | 10.14% |
| Fastest Growing Segment | Drug Development and Discovery |
| Largest Market | North America |
Market Overview
Global Induced Pluripotent Stem Cells Production Market has valued at USD 1.24 billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 10.14% through 2028. Induced pluripotent stem cells (iPSCs) represent a groundbreaking advancement in regenerative medicine. These cells have the potential to transform the treatment landscape for a wide range of diseases and conditions, from neurodegenerative disorders to cardiovascular diseases. As the iPSC technology continues to evolve, so does the market for their production.
The iPSC production market has been steadily growing over the past decade, driven by increasing research and development activities in the field of regenerative medicine and drug discovery.
Key Market Drivers
Expanding Therapeutic Applications
The therapeutic potential of iPSCs continues to broaden. These cells are being explored as candidates for treating a wide range of diseases, including neurodegenerative disorders like Parkinson's and Alzheimer's, heart diseases, diabetes, and more. With each new therapeutic application, the market for iPSC production expands. Patients and healthcare providers are eager for innovative treatment options, further driving the demand for iPSCs.
The expanding therapeutic applications of iPSCs are revolutionizing the way we approach disease treatment and prevention. They offer personalized solutions, improved disease modeling, and a bridge to regenerative medicine that was once considered science fiction. As these applications advance, they drive the demand for iPSC production, spurring innovation and investment in the field. Moreover, the potential cost savings associated with iPSC-based therapies, such as reduced hospitalization, fewer complications, and improved outcomes, make them an attractive option for healthcare providers and payers. This further incentivizes the growth of the iPSCs production market, as companies and researchers strive to meet the increasing demand for iPSCs and their derivatives.
Drug Discovery and Toxicity Testing
iPSCs have become invaluable tools in the pharmaceutical industry. They are used to model diseases, screen potential drug candidates, and assess drug toxicity. Compared to traditional methods, iPSC-based assays offer greater accuracy and efficiency, reducing costs and time in the drug development process. As the demand for more efficient drug discovery and safety testing methods grows, so does the demand for iPSCs in production.
This approach enables personalized medicine by tailoring treatment strategies to individual patients.
Technological Advancements
Advancements in iPSC production techniques have made the process more efficient and cost-effective. Automation, genome editing technologies like CRISPR-Cas9, and optimized culture conditions have all contributed to the streamlining of iPSC production. These technological innovations not only make iPSCs more accessible to researchers but also enable their use in larger-scale applications, such as cell-based therapies.
Automated systems equipped with robotics and advanced software have streamlined the generation, maintenance, and differentiation of iPSCs, significantly reducing the time and labor required for these processes. This increased efficiency has not only accelerated research efforts but also lowered production costs, making iPSC technology more accessible to researchers and industry players alike. Another game-changing technological advancement is the development of 3D cell culture systems and bioprinting techniques. Traditional 2D cell culture models have limitations when it comes to replicating the complex three-dimensional environments of human tissues. 3D cell cultures, on the other hand, offer a more physiologically relevant platform for iPSC differentiation and tissue engineering. Advanced bioprinting technologies enable the precise placement of iPSC-derived cells and biomaterials, allowing for the creation of intricate tissue structures. This has profound implications for drug screening, disease modeling, and eventually, the transplantation of lab-grown organs and tissues.
Increasing Awareness and Acceptance
Key Market Challenges
Cost of Production
One of the primary challenges facing the iPSCs production market is the high cost associated with generating and maintaining iPSCs. The complex and resource-intensive process of reprogramming adult cells into iPSCs requires specialized equipment, skilled personnel, and expensive culture media. These costs are a significant barrier for researchers and companies looking to scale up iPSC production for clinical applications. As a result, the overall cost of iPSC-based therapies remains prohibitively high, limiting their accessibility to a broader patient population.
Quality Control and Standardization
Ensuring the quality and consistency of iPSCs is essential for their safe and effective use in clinical settings. However, maintaining consistent quality across iPSC lines can be challenging due to variations in cell culture conditions, reprogramming techniques, and genetic backgrounds of donor cells. Standardization of iPSC production processes and rigorous quality control measures are necessary to address this challenge. Without a standardized approach, it becomes difficult to compare results across studies and establish a solid regulatory framework, hampering the growth of the iPSC production market.
Competition from Alternative Therapies
Pharmaceutical dissolution testing generates vast amounts of data, and effectively managing and analyzing this data is a significant challenge. Laboratories must invest in robust data management systems to store, retrieve, and interpret test results accurately. Furthermore, data integrity and traceability are crucial in pharmaceutical testing, as any errors or inconsistencies can have severe consequences. Additionally, the interpretation of dissolution test results requires expertise and a deep understanding of pharmaceutical science. Laboratories must employ skilled scientists and analysts who can translate raw data into meaningful insights for drug manufacturers. The shortage of trained professionals in this field adds to the challenges faced by the Induced Pluripotent Stem Cells Production market.
Key Market Trends
Growing Applications in Disease Modeling and Drug Development
One of the primary drivers of the iPSC production market is the expanding range of applications in disease modeling and drug development. iPSCs can be derived from patients with specific genetic mutations, allowing researchers to create disease-specific cell lines. This enables the development of more accurate and relevant disease models for studying diseases like Parkinson's, Alzheimer's, and genetic disorders. Pharmaceutical companies are increasingly using iPSCs to screen potential drug candidates, reducing the cost and time associated with traditional drug development processes. As the need for personalized medicine grows, so does the demand for iPSCs in disease modeling and drug testing.
Technological Advancements in Reprogramming Techniques
Efficient reprogramming techniques are vital for the widespread adoption of iPSCs. Over the years, significant advancements have been made in this area, making it easier and more cost-effective to generate iPSCs. The development of non-integrating reprogramming methods, such as Sendai virus and synthetic mRNA-based approaches, has eliminated concerns about genomic integration and increased the safety of iPSC generation. Furthermore, the optimization of small molecules and growth factors used in the reprogramming process has enhanced the efficiency and speed of iPSC production, making it more accessible to researchers and clinicians. The shift from traditional 2D cell culture to 3D cell culture and organoid technologies is another trend shaping the iPSC production market. 3D cultures and organoids better mimic the complex tissue architecture and microenvironment found in the human body, making them valuable tools for disease modeling, drug testing, and regenerative medicine. iPSCs play a crucial role in the development of these models, as they can be differentiated into various cell types and organized into 3D structures that closely resemble human tissues and organs.
Segmental Insights
Product Insights
Based on the products, the consumables and kits segment emerged as the dominant player in the global market for Induced Pluripotent Stem Cells Production in 2022.
Application Insights
Based on the Application, drug development and discovery segment emerged as the dominant player in the global market for Induced Pluripotent Stem Cells Production in 2022.
Regional Insights
North America emerged as the dominant player in the global Induced Pluripotent Stem Cells Production market in 2022, holding the largest market share. This is on account of its advanced healthcare infrastructure, strong adoption of technology, and robust research and development activities. North America, particularly the United States, is home to state-of-the-art pharmaceutical research and testing facilities. The availability of advanced dissolution testing equipment and technology in the region ensures precision, accuracy, and efficiency in testing services.
Recent Developments
- In October 2022, Japanese companiesREPROCELL, Inc. and JTB Corp. established a business partnership. Bothbusinesses will work together to start selling the "Personal iPS"service to customers abroad as well as in Japan. In December 2020, REPROCELL,Inc. introduced this service.
- In July 2021, diabetes medicine has beenin-licensed by SCM Lifescience Co. Ltd., a South Korean cell therapydevelopment business, from Allele Biotechnology and Pharmaceuticals, Inc., a UScompany. The diabetes treatment is a pancreatic beta cell therapy made fromiPSCs, and the contract is worth USD 0.75 million.
Key Market Players
- Lonza Group
- Axol Biosciences Ltd.
- Evotec Se
- Hitachi Ltd.
- Reprocells Inc.
- Fate Therapeutics.
- Thermo Fisher Scientific, Inc.
- Merck Kgaa
- Stemcellsfactory Iii
- Applied Stemcells Inc.
| By Process | By Product | By End-user | By Application | By Region |
|
|
|
|
|
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy